The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease
Open accessPublished version of a preprint
The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Background: The effect of the COVID-19 pandemic on people with Parkinson’s disease (PD) is poorly understood. Objective: To rapidly identify areas of need and improve care in people with PD during the COVID-19 pandemic, we deployed a survey to assess COVID-19 symptoms and the pandemic’s effect among those with and without COVID-19. Methods: People with and without PD participating in the online study Fox Insight (FI) were invited to complete a survey between April 23 and May 23, 2020. Among people reporting COVID-19 diagnoses, we compared symptoms and outcomes in people with and without PD. Among people not reporting COVID-19, we assessed access to healthcare and services and PD symptoms. Results: 7,209/9,762 active FI users responded (approximately 74% response rate), 5,429 people with PD and 1,452 without PD. COVID-19 diagnoses were reported by 51 people with and 26 without PD. Complications were more frequent in people with longer PD duration. People with PD and COVID-19 experienced new or worsening motor (63%) and nonmotor (75%) symptoms. People with PD not diagnosed with COVID-19 reported disrupted medical care (64%), exercise (21%), and social activities (57%), and worsened motor (43%) and non-motor (52%) symptoms. Disruptions were more common for those living alone, with lower income and non-White race. Conclusions: The COVID-19 pandemic is associated with wide-ranging effects on people with PD, and certain groups may be at particular risk. FI provides a rapid, patient-centered means to assess these effects and identify needs that can be used to improve the health of people with PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, COVID-19 exacerbates both motor and nonmotor symptoms in PD patients, particularly urinary issues and fatigue.285,286”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [286]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The social isolation imposed by the COVID-19 pandemic greatly affected people with PD (Brown et al., 2020; van der Heide et al., 2020).”
From Online Mindfulness-Based Cognitive Therapy for People with Parkinson’s Disease and Their Caregivers: a Pilot Study (2022) · cites this paper as Brown et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Psychological Impact of Quarantine and How to Reduce It: Rapid Review of the Evidence
Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N., & Rubin, G. J. (2020) · doi:10.2139/ssrn.3532534 · Cited by 16,394
The psychological impact of quarantine and how to reduce it: Rapid review of the evidence
Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N., & Rubin, G. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30460-8 · Cited by 16,378 · cited 1×
“In the elderly, social isolation has been associated with more rapid cognitive decline [38], and quarantine in particular can lead to lasting psychological effects [39].”
BackgroundClinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750 · cited 1×
“Exacerbation of PD symptoms during COVID-19 may in part be due to the inflammatory reaction characteristic of the disease [25].”
BackgroundNeurologic features in severe SARS-CoV-2 infection
Helms, J., Kremer, S., Merdji, H., Clere-Jehl, R., Schenck, M., Kummerlen, C., Collange, O., Boulay, C., Fafi-Kremer, S., Ohana, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2008597 · Cited by 2,674 · cited 1×
“Although COVID-19 has been associated with changes on neuroimaging [20, 21] and SARS-CoV2 RNA has been detected in cerebrospinal fluid [22,”
MethodCDC COVID-19 Response Team, CDC COVID-19 Response Team, Chow, N., Fleming-Dutra, K., Gierke, R., Hall, A., Hughes, M., Pilishvili, T., Ritchey, M., Roguski, K., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6913e2 · Cited by 1,404
Giacomelli, A., Pezzati, L., Conti, F., Bernacchia, D., Siano, M., Oreni, L., Rusconi, S., Gervasoni, C., Ridolfo, A. L., Rizzardini, G., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa330 · Cited by 1,326
Impact of sex and gender on COVID-19 outcomes in Europe
Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R., & Klein, S. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00304-9 · Cited by 1,306 · cited 1×
“Men with COVID-19 have been reported to have more severe disease than women [29, 30], while women may be more susceptible [31].”
BackgroundNeuropathological features of Covid-19
Solomon, I. H., Normandin, E., Bhattacharyya, S., Mukerji, S. S., Keller, K., Ali, A. S., Adams, G., Hornick, J. L., Padera, R. F., & Sabeti, P. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2019373 · Cited by 815 · cited 1×
“23], a recent autopsy series of patients that died with COVID-19—all of whom experienced altered mental status—did not find immunohistochemical evidence of encephalitis or viral invasion into brain tissue [24].”
BackgroundSmell dysfunction: a biomarker for COVID‐19
Moein, S. T., Hashemian, S. M., Mansourafshar, B., Khorram‐Tousi, A., Tabarsi, P., & Doty, R. L. (2020) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22587 · Cited by 794 · cited 2×
“Hyposmia has been well described in people with COVID-19 [26].”
BackgroundResultAssociation of olfactory dysfunction with risk for future Parkinson's disease
Ross, G. W., Petrovitch, H., Abbott, R. D., Tanner, C. M., Popper, J., Masaki, K., Launer, L., & White, L. R. (2008) · Annals of Neurology · doi:10.1002/ana.21291 · Cited by 742 · cited 1×
“Hyposmia predicts PD-associated clinical and pathological changes [47, 48].”
BackgroundSelf-citationNeurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry
Romero-Sánchez, C. M., Díaz-Maroto, I., Fernández-Díaz, E., Sánchez-Larsen, Á., Layos-Romero, A., García-García, J., González, E., Redondo-Peñas, I., Perona-Moratalla, A. B., Del Valle-Pérez, J. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009937 · Cited by 737
Social isolation: a predictor of mortality comparable to traditional clinical risk factors
Pantell, M., Rehkopf, D., Jutte, D., Syme, S. L., Balmes, J., & Adler, N. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301261 · Cited by 696 · cited 1×
“Among those not infected, social distancing guidelines may lead to social isolation, a known risk factor for poor outcomes [5], and reduced access to care [6], all of which are additional concerns of people with PD [1].”
BackgroundCrawford, A., & Serhal, E. (2020) · Journal of Medical Internet Research · doi:10.2196/19361 · Cited by 630
Saleh, A., & Bista, K. (2017) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v13i29.487 · Cited by 481 · cited 1×
“Online surveys often have a lower response rate than in-person research [43], and many people may have had difficulty finding time to respond during the pandemic.”
BackgroundPrevalence of anxiety in Parkinson's disease: A systematic review and meta‐analysis
Broen, M. P. G., Narayen, N. E., Kuijf, M. L., Dissanayaka, N. N. W., & Leentjens, A. F. G. (2016) · Movement Disorders · doi:10.1002/mds.26643 · Cited by 457
Louapre, C., Collongues, N., Stankoff, B., Giannesini, C., Papeix, C., Bensa, C., Deschamps, R., Créange, A., Wahab, A., Pelletier, J., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2581 · Cited by 455 · cited 1×
“Preliminary reports from the CDC indicate that a high proportion of people with COVID-19 and neurologic disorders require hospitalization [16], and severity of other neurologic conditions has been associated with complications of COVID-19 [17].”
BackgroundAPOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort
Kuo, C.-L., Pilling, L. C., Atkins, J. L., Masoli, J. A. H., Delgado, J., Kuchel, G. A., & Melzer, D. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glaa131 · Cited by 388
Politi, L. S., Salsano, E., & Grimaldi, M. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2125 · Cited by 369
Is increased blinking a form of blepharospasm?
(2013) · CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) · doi:10.1212/wnl · Cited by 355
Helmich, R. C., & Bloem, B. R. (2020) · Journal of Parkinson's Disease · doi:10.3233/jpd-202038 · Cited by 300 · cited 1×
“Individuals with PD are at high risk for anxiety [40], and may be particularly vulnerable to external stressors [41].”
BackgroundGender-related differences in the burden of non-motor symptoms in Parkinson’s disease
Martinez-Martin, P., Falup Pecurariu, C., Odin, P., Hilten, J. J., Antonini, A., Rojo-Abuin, J. M., Borges, V., Trenkwalder, C., Aarsland, D., Brooks, D. J., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-011-6392-3 · Cited by 282
Sars-Cov-2: Underestimated damage to nervous system
Zhou, L., Zhang, M., Wang, J., & Gao, J. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101642 · Cited by 278 · cited 1×
“001 PD Duration, N (%) 0 – 3y 21 (41) -1628 (30) -3 – 6y 12 (24) -1649 (31) -6 – 9y 9 (18) -981 (18) -> 9y 9 (18) -1114 (21) -Comorbidities, N(%) Immunocompromised 11 (22) 8 (31) 0.”
Early postmortem brain MRI findings in COVID-19 non-survivors
Coolen, T., Lolli, V., Sadeghi, N., Rovai, A., Trotta, N., Taccone, F. S., Creteur, J., Henrard, S., Goffard, J.-C., Dewitte, O., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010116 · Cited by 256
Self-citationEarly postmortem brain MRI findings in COVID-19 non-survivors
Coolen, T., Lolli, V., Sadeghi, N., Rovaï, A., Trotta, N., Taccone, F. S., Creteur, J., Henrard, S., Goffard, J.-C., De Witte, O., et al. (2020) · doi:10.1101/2020.05.04.20090316 · Cited by 256
Self-citationSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System
De Felice, F. G., Tovar-Moll, F., Moll, J., Munoz, D. P., & Ferreira, S. T. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.04.004 · Cited by 247
Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid
Virhammar, J., Kumlien, E., Fällmar, D., Frithiof, R., Jackmann, S., Sköld, M. K., Kadir, M., Frick, J., Lindeberg, J., Olivero-Reinius, H., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010250 · Cited by 245 · cited 1×
“001 PD Duration, N (%) 0 – 3y 21 (41) -1628 (30) -3 – 6y 12 (24) -1649 (31) -6 – 9y 9 (18) -981 (18) -> 9y 9 (18) -1114 (21) -Comorbidities, N(%) Immunocompromised 11 (22) 8 (31) 0.”
Outcome of Parkinson's Disease Patients Affected by COVID‐19
Antonini, A., Leta, V., Teo, J., & Chaudhuri, K. R. (2020) · Movement Disorders · doi:10.1002/mds.28104 · Cited by 232
The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders
Bloem, B. R., Dorsey, E. R., & Okun, M. S. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1452 · Cited by 224 · cited 2×
“Rapid changes in healthcare delivery to people with PD have been developed, including recommendations on implementing telemedicine [7] and managing advanced therapies remotely [8, 9], but these resources are not universally available [10].”
BackgroundEncephalitis lethargica: 100 years after the epidemic
Hoffman, L. A., & Vilensky, J. A. (2017) · Brain · doi:10.1093/brain/awx177 · Cited by 195
Association of olfactory dysfunction with incidental Lewy bodies
Ross, G. W., Abbott, R. D., Petrovitch, H., Tanner, C. M., Davis, D. G., Nelson, J., Markesbery, W. R., Hardman, J., Masaki, K., Launer, L., et al. (2006) · Movement Disorders · doi:10.1002/mds.21076 · Cited by 194 · cited 1×
“Hyposmia predicts PD-associated clinical and pathological changes [47, 48].”
BackgroundSelf-citationProlonged social isolation of the elderly during COVID-19: Between benefit and damage
Plagg, B., Engl, A., Piccoliori, G., & Eisendle, K. (2020) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2020.104086 · Cited by 186
Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study
Cilia, R., Bonvegna, S., Straccia, G., Andreasi, N. G., Elia, A. E., Romito, L. M., Devigili, G., Cereda, E., & Eleopra, R. (2020) · Movement Disorders · doi:10.1002/mds.28170 · Cited by 185 · cited 2×
“Others have similarly reported worsening of PD-related symptoms either as presenting signs of COVID-19 [4] or during the course of the infection [2, 3].”
BackgroundResultNew York City Department of Health and Mental Hygiene (DOHMH) COVID-19 Response Team, New York City Department of Health and Mental Hygiene (DOHMH) COVID-19 Response Team, Olson, D. R., Huynh, M., Fine, A., Baumgartner, J., Castro, A., Chan, H. T., Daskalakis, D., Devinney, K., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6919e5 · Cited by 176
Friedler, B., Crapser, J., & McCullough, L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1377-9 · Cited by 174
LRRK2 regulation of immune-pathways and inflammatory disease
Wallings, R. L., & Tansey, M. G. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180463 · Cited by 173
Pleasure, S. J., Green, A. J., & Josephson, S. A. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1065 · Cited by 171 · cited 1×
“This association, among other neurologic manifestations in people with COVID-19 [49, 50], has prompted worries about the possibility of SARS-CoV-2 infection triggering long-term neurodegeneration [51, 52], as was observed following the 1917-1918 pandemic [53].”
BackgroundSex specific cognitive differences in Parkinson disease
Reekes, T. H., Higginson, C. I., Ledbetter, C. R., Sathivadivel, N., Zweig, R. M., & Disbrow, E. A. (2020) · npj Parkinson s Disease · doi:10.1038/s41531-020-0109-1 · Cited by 135
Meini, S., Suardi, L., Busoni, M., Roberts, A. T., & Fortini, A. (2020) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-020-06102-8 · Cited by 124 · cited 1×
“Anosmia in COVID-19, though usually transient [45], may represent true viral invasion of the olfactory bulbs [46].”
BackgroundPotential sex differences in nonmotor symptoms in early drug-naive Parkinson disease
Liu, R., Umbach, D. M., Peddada, S. D., Xu, Z., Tröster, A. I., Huang, X., & Chen, H. (2015) · Neurology · doi:10.1212/wnl.0000000000001609 · Cited by 116 · cited 1×
“Other studies have similarly suggested that women with PD report more mood symptoms [32, 33] and fewer cognitive problems [34] than men, and our findings may be more reflective of differences in symptoms between men and women with PD rather than reflecting changes due to the pandemic.”
ResultFasano, A. A., Antonini, A., Katzenschlager, R., Krack, P., Odin, P., Evans, A. H., Foltynie, T., Volkmann, J., & Merello, M. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12965 · Cited by 113
Minimum Response Rates for Survey Research
Livingston, E. H. (2012) · Archives of Surgery · doi:10.1001/archsurg.2011.2169 · Cited by 111 · cited 1×
“Our response rate was moderate at 74% of active FI users, but still above the goal suggested for survey-based research [42].”
ResultSmolensky, L., Amondikar, N., Crawford, K., Neu, S., Kopil, C. M., Daeschler, M., Riley, L., 23andMe Research Team, Agee, M., Alipanahi, B., et al. (2020) · Scientific Data · doi:10.1038/s41597-020-0401-2 · Cited by 109
Self-citationGendered effects on inflammation reaction and outcome of COVID‐19 patients in Wuhan
Qin, L., Li, X., Shi, J., Yu, M., Wang, K., Tao, Y., Zhou, Y., Zhou, M., Xu, S., Wu, B., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26137 · Cited by 103
Louapre, C., Collongues, N., Stankoff, B., Giannesini, C., Papeix, C., Bensa, C., Deschamps, R., Créange, A., Wahab, A., Pelletier, J., et al. (2020) · Multiple Sclerosis Journal · Cited by 103
Bhidayasiri, R., Virameteekul, S., Kim, J., Pal, P. K., & Chung, S. J. (2020) · Journal of Movement Disorders · doi:10.14802/jmd.20042 · Cited by 95 · cited 1×
“This association, among other neurologic manifestations in people with COVID-19 [49, 50], has prompted worries about the possibility of SARS-CoV-2 infection triggering long-term neurodegeneration [51, 52], as was observed following the 1917-1918 pandemic [53].”
BackgroundAge-dependent Gender Differences in COVID-19 in Mainland China: Comparative Study
Qian, J., Zhao, L., Ye, R., Li, X.-J., & Liu, Y. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa683 · Cited by 91 · cited 1×
“Men with COVID-19 have been reported to have more severe disease than women [29, 30], while women may be more susceptible [31].”
BackgroundSelf-reported needs of patients with Parkinson’s disease during COVID-19 emergency in Italy
Schirinzi, T., Cerroni, R., Lazzaro, G. D., Liguori, C., Scalise, S., Bovenzi, R., Conti, M., Garasto, E., Mercuri, N. B., Pierantozzi, M., et al. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04442-1 · Cited by 76 · cited 2×
“Our goals were to (1) understand the symptoms and outcomes of SARS CoV-2 infection in people with and without PD, (2) determine its effects on PD symptoms; and (3) understand the effects of the pandemic and associated public health measures.”
BackgroundMethodBrugger, F., Erro, R., Balint, B., Kägi, G., Barone, P., & Bhatia, K. P. (2015) · npj Parkinson's Disease · doi:10.1038/npjparkd.2015.14 · Cited by 73
Fei, Y., Johansson, A. L. V., Pedersen, N. L., Fang, F., Gatz, M., & Wirdefeldt, K. (2016) · Medicine · doi:10.1097/md.0000000000004337 · Cited by 69
Feasibility of Virtual Research Visits in Fox Trial Finder
Dorsey, E. R., Wagner, J. D., Bull, M. T., Rizzieri, A., Grischkan, J. A., Achey, M. A., Sherer, T., Chowdhury, S., Meunier, C. C., Cappelletti, L., et al. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150549 · Cited by 64
Recommendations for Deep Brain Stimulation Device Management During a Pandemic
Miocinovic, S., Ostrem, J. L., Okun, M. S., Bullinger, K. L., Riva‐Posse, P., Gross, R. E., & Buetefisch, C. M. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202072 · Cited by 61 · cited 1×
“Rapid changes in healthcare delivery to people with PD have been developed, including recommendations on implementing telemedicine [7] and managing advanced therapies remotely [8, 9], but these resources are not universally available [10].”
BackgroundClinical Characteristics of Exacerbations in Parkinson Disease
Zheng, K. S., Dorfman, B. J., Christos, P. J., Khadem, N. R., Henchcliffe, C., Piboolnurak, P., & Nirenberg, M. J. (2012) · The Neurologist · doi:10.1097/nrl.0b013e318251e6f2 · Cited by 54
Rapid worsening in Parkinson's disease may hide COVID-19 infection
Hainque, É., & Grabli, D. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.05.008 · Cited by 52
D’Souza, T., & Rajkumar, A. P. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.28 · Cited by 39
Which features of Parkinson's disease predict earlier exit from the workforce?
Armstrong, M. J., Gruber‐Baldini, A. L., Reich, S. G., Fishman, P. S., Lachner, C., & Shulman, L. M. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.08.005 · Cited by 29
Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person
Chahine, L. M., Study, O. B. O. T. F. I., Chin, I., Caspell‐Garcia, C., Standaert, D. G., Brown, E. G., Smolensky, L., Arnedo, V., Daeschler, D., Riley, L., et al. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191808 · Cited by 24
Self-citationThe challenge of managing parkinson's disease patients during the COVID-19 pandemic
Dhamija, R. K., & Garg, D. (2020) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_295_20 · Cited by 21
Research works printed but not linked: 3
- 10.1001/jama-neurol.2020.1452 · doi:10.1001/jama-neurol.2020.1452
- 10.1001/jmaneurol.2020.2581 · doi:10.1001/jmaneurol.2020.2581
- 10.1002/air.22680 · doi:10.1002/air.22680
Cited by
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
Albornoz, E. A., Amarilla, A. A., Modhiran, N., Parker, S., Li, X. X., Wijesundara, D. K., Aguado, J., Zamora, A. P., McMillan, C. L. D., Liang, B., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01831-0 · Cited by 180
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
“285,286 In conclusion, SARS-CoV-2 may accelerate the ageing process while increasing the risk of neurodegenerative diseases among older adults.”
Liu, L., Ni, S., Yan, W., Lu, Q.-D., Zhao, Y., Xu, Y. Y., Mei, H., Shi, L., Yuan, K., Han, Y., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101111 · Cited by 150
“We included 27 studies (132,727,798 participants) for susceptibility [20-24,30-37,108-119,132,166], 56 studies (83,097,968 participants) for illness severity [21,24,28,31,32,34,38-41,4362,83,108,110,116,117,120-138,167,169], and 115 studies (88,878,662 participants) for mortality [21,23,28,29,31,32,34,35,3844,46-48,51…”
The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It
Malik, J. A., Ahmed, S., Shinde, M., Almermesh, M. H. S., Alghamdi, S., Hussain, A., & Anwar, S. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.02.006 · Cited by 112
“Non-motor symptoms were reported as new or deteriorating in all domains: mood (20 % new, 51 % worsening), cognitive (7.8% new, 41 % worsening), sleep (12 % new, 59 % worsening), and autonomic dysfunction (12 % new, 59 % worsening) (Brown et al., 2020).”
InfluentialThe Role of Diet and Dietary Patterns in Parkinson’s Disease
Knight, E., Geetha, T., Burnett, D. O., & Babu, J. R. (2022) · Nutrients · doi:10.3390/nu14214472 · Cited by 111
Metadata
- Authors
- Brown, E. G., Chahine, L. M., Goldman, S. M., Korell, M., Mann, E., Kinel, D. R., Arnedo, V., Marek, K. L., & Tanner, C. M.
- Affiliations
- University of California, San Francisco (US)
- University of Pittsburgh (US)
- University of Rochester (US)
- Michael J. Fox Foundation (US)
- Institute for Neurodegenerative Disorders (US)
- Corresponding author
- Tanner, Caroline M.
- ORCID
- Venue
- Journal of Parkinson's Disease
- Publisher
- SAGE Publications
- Published
- 2020-10-27
- Volume
- 10
- Issue
- 4
- Pages
- 1365-1377
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC7683050
- OpenAlex
- W3086892979
- Cited by
- 177
- References
- 54
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 29 · 2023: 25 · 2022: 49 · 2021: 48 · 2020: 4
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- U.S. Department of Defense
- Michael J. Fox Foundation for Parkinson's Research
- Biogen
- University of Pittsburgh
- Oscar Health
- National Institutes of Health
- Centers for Disease Control and Prevention
- University of California, San Francisco
- National Institute for Occupational Safety and Health
- Agency for Toxic Substances and Disease Registry
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
- Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
- Keywords
- Parkinson's disease, COVID-19 pandemic, COVID-19 symptoms, motor symptoms, non-motor symptoms, health care access, living alone, income inequality, racial disparities, disease duration
- MeSH terms
- COVID-19, Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Health Services Accessibility, Humans, Male, Middle Aged, Parkinson Disease, Pneumonia, Viral, Surveys and Questionnaires, Coronavirus Infections, Young Adult, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.